BRCA1 in hormone-responsive cancers

Trends in Endocrinology and Metabolism

Volumn 14, Issue 8, 2003, Pages 378-385

  Rosen, Eliot M ^a   Fan, Saijun ^a   Pestell, Richard G ^a   Goldberg, Itzhak D ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CARCINOGEN; ESTROGEN RECEPTOR ALPHA;

APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CANCER RISK; CANCER SUSCEPTIBILITY; CELL CYCLE; DNA REPLICATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; HORMONE SENSITIVITY; HUMAN; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 0141895067     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2003.08.001     Document Type: Review

References (98)

1. Miki, Y. et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71
2. Wooster, R. et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792
3. Cornelis, R.S. et al. (1995) High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCA1-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer 13, 203-210
4. Futreal, PA. et al. (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120-122
5. Wilson, C.A. et al. (1999) Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat. Genet. 21, 236-240
6. Esteller, M. et al. (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92, 564-569
7. Thompson, D. et al. (2002) Cancer incidence in BRCA1 mutation carriers. J. Natl. Cancer Inst. 94, 1358-1365
8. Breast Cancer Linkage Consortium, (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases. Breast cancer linkage consortium. Lancet 349, 1505-1510
9. Archey, W.B. et al. (2002) Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. Oncogene 21, 7034-7041
10. Grushko, T.A. et al. (2002) Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 62, 1481-1488
11. Vaziri, S.A. et al. (2001) Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol. Pathol. 54, 259-263
12. Kauraniemi, P. et al. (2000) MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res. 60, 5323-5328
13. Wolmark, N. and Dunn, B.K. (2001) The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann. N. Y. Acad. Sci. 949, 99-108
14. King, M.C. et al. (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA 286, 2251-2256
15. Monteiro, A.N. et al. (1996) Evidence for a transcription activation function of BRCA1 C-terminal region. Proc. Natl. Acad. Sci. U. S. A. 93, 13595-13599
16. Hashizume, R. et al. (2001) The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 276, 14537-14540
17. Ruffner, H. et al. (2001) Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl. Acad. Sci. U. S. A. 98, 5134-5139
18. Bork, P. et al. (1997) A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J. 11, 68-76
19. Thakur, S. et al. (1997) Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol. Cell. Biol. 17, 444-452
20. Rodriguez, J.A. and Henderson, B.R. (2000) Identification of a functional nuclear export sequence in BRCA1. J. Biol. Chem. 275, 38589-38596
21. Altiok, S. et al. (1999) Heregulin induces phosphorylation of BRCA1 through phosphatidyl-inositol 3-kinase/AKT in breast cancer cells. J. Biol. Chem. 274, 32274-32278
22. Rajan, J.V. et al. (1996) Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammalian epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 93, 3078-3083
23. Thomas, J.E. et al. (1997) Induction of phosphorylation of BRCA1 during the cell cycle and after DNA damage. Cell Growth Differ. 8, 801-809
24. Ruffner, H. et al. (1999) BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. Mol. Cell. Biol. 19, 4843-4854
25. Marks, J.R. et al. (1997) BRCA1 is not directly responsive to estrogen. Oncogene 14, 115-121
26. Fan, S. et al. (1999) Co-ordinate down-regulation of BRCA1, BRCA2, Rad51, and p300 during the response to damage in human prostate cancer cell lines. Prostate 40, 37-49
27. Fan, S. et al. (1998) BRCA1 as a human prostate tumor suppressor: modulation of proliferation, damage responses, and expression of regulatory proteins. Oncogene 16, 3069-3083
28. Beger, C. et al. (2001) Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc. Natl. Acad. Sci. U. S. A. 98, 130-135
29. MacLachlan, T.K. et al. (2000) Repression of BRCA1 through a feedback loop involving p53. J. Biol. Chem. 275, 31869-31875
30. Atlas, E. et al. (2000) GA-binding protein α/β is a critical regulator of the BRCA1 promoter. Oncogene 19, 1933-1940
31. Budhram-Mahadeo, V. et al. (1999) The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells. Oncogene 18, 6684-6691
32. Campbell, M.J. et al. (2000) The anti-proliferative effects of 1α 25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 19, 5091-5097
33. Tirkkonen, M. et al. (1997) Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 57, 1222-1227
34. Gowen, L.C. et al. (1998) BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281, 1009-1012
35. Moynahan, M.E. et al. (2001) Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 61, 4842-4850
36. Wang, Q. et al. (2001) Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1. Oncogene 20, 4640-4649
37. Hartman, A.R. and Ford, J.M. (2002) BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat. Genet. 32, 180-184
38. Bhattacharyya, A. et al. (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275, 23899-23903
39. Cantor, S.B. et al. (2001) BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105, 149-160
40. Venkitaraman, A.R. (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108, 171-182
41. Rosen, E.M. et al. (2003) The BRCA1 gene in breast cancer. J. Cell. Physiol. 196, 19-41
42. Hakem, R. et al. (1996) The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85, 1009-1023
43. Fan, S. et al. (2001) Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1. Oncogene 20, 8215-8235
44. Harkin, D.P. et al. (1999) Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 97, 575-586
45. Yan, Y. et al. (2002) BRCA1-induced apoptosis involves inactivation of ERK1/2 activities. J. Biol. Chem. 277, 33422-33430
46. Yarden, R.I. and Brody, L.C. (1999) BRCA1 interacts with components of the histone deacetylase complex. Proc. Natl. Acad. Sci. U. S. A. 96, 4983-4988
47. Aprelikova, O.N. et al. (1999) BRCA1-associated growth arrest is RB-dependent. Proc. Natl. Acad. Sci. U. S. A. 96, 11866-11871
48. Anderson, S.F. et al. (1998) BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet. 19, 254-256
49. Pao, G.M. et al. (2000) CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc. Natl. Acad. Sci. U. S. A. 97, 1020-1025
50. Sum, E.Y. et al. (2002) The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity. J. Biol. Chem. 277, 7849-7856
51. Bochar, D.A. et al. (2000) BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 102, 257-265
52. Ye, Q. et al. (2001) BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations. J. Cell Biol. 155, 911-921
53. Fan, W. et al. (2002) BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. J. Biol. Chem. 277, 8061-8067
54. WAF1/CIP1. Nature 389, 187-190
55. Williamson, E.A. et al. (2002) BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene 21, 3199-3206
56. Chappuis, P.O. et al. (2000) Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J. Clin. Oncol. 18, 4045-4052
57. Wang, Q. et al. (1999) BRCA1 binds c-Myc and inhibits its transcritional and transforming activity in cells. Oncogene 17, 1939-1948
58. Li, H. et al. (2002) A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J. Biol. Chem. 277, 20965-20973
59. Ouichi, T. et al. (1998) BRCA1 regulates p53-dependent gene expression. Proc. Natl. Acad. Sci. U. S. A. 95, 2302-2306
60. MacLachlan, T.K. et al. (2002) BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol. Cell. Biol. 22, 4280-4292
61. Hu, Y.F. and Li, R. (2002) JunB potentiates function of BRCA1 activation domain 1 (AD1) through a coiled-coil-mediated interaction. Genes Dev. 16, 1509-1517
62. Ouchi, T. et al. (2000) Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-γ target genes. Proc. Natl. Acad. Sci. U. S. A. 97, 5208-5213
63. Ma, Y.X. et al. (2003) Role of BRCA1 in heat shock response. Oncogene 22, 10-27
64. Dickson, R.B. and Stancel, G.M. (2000) Estrogen receptor-mediated processes in normal and cancer cells. J. Natl. Cancer Inst. Monogr. 27, 135-145
65. Fan, S. et al. (1999) BRCA1 inhibits estrogen receptor signaling in transfected cells. Science 284, 1354-1356
66. Fan, S. et al. (2001) Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20, 77-87
67. Fan, S. et al. (2002) p300 modulates BRCA1 inhibition of estrogen receptor activity. Cancer Res. 62, 141-151
68. Kawai, H. et al. (2002) Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21, 7730-7739
69. Zheng, L. et al. (2001) BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 98, 9587-9592
70. Balk, S.P. (2002) Androgen receptor as a target in androgen-independent prostate cancer. Urology 60 (Suppl. 1), 132-139
71. Yeh, S. et al. (2000) Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 97, 11256-11261
72. Park, J.J. et al. (2000) Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor. Cancer Res. 60, 5946-5949
73. Heisler, L.E. et al. (1997) Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol. Cell. Endocrinol. 126, 59-73
74. Ando, S. et al. (2002) Breast cancer: from estrogen to androgen receptor. Mol. Cell. Endocrinol. 193, 121-128
75. Ferro, P. et al. (2002) The androgen receptor CAG repeat: a modifier of carcinogenesis? Mol. Cell. Endocrinol. 193, 109-120
76. Shertzer, H.G. and Senft, A.P. (2000) The micronutrient indole-3-carbinol: implications for disease and chemoprevention. Drug Metabol. Drug Interact. 17, 159-188
77. Bradlow, H.L. et al. (1991) Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12, 1571-1574
78. Meng, Q. et al. (2000) Suppression of breast cancer invasion and migration mediated by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. J. Mol. Med. 78, 155-165
79. Meng, Q. et al. (2000) Indole-3-carbinol is a negative regulator of estrogen receptor-a signaling in human tumor cells. J. Nutr. 130, 2927-2931
80. Carter, T.H. et al. (2002) Diindolylmethane alters gene expression in human keratinocytes. J. Nutr. 132, 3314-3324
81. Meng, Q. et al. (2000) Inhibitory effects of indole-3-carbinol on invasion and migration in human breast cancer cells. Breast Cancer Res. Treat. 63, 147-152
82. Meng, Q. et al. (2000) Stimulation of cell invasion and migration by alcohol in breast cancer cells. Biochem. Biophys. Res. Commun. 273, 448-453
83. Fan, S. et al. (2000) Advances in brief. Alcohol stimulates estrogen receptor signaling in human breast cancer cell lines. Cancer Res. 60, 5635-5639
84. Jeffy, B.D. et al. (2002) Epigenetics of breast cancer: polycyclic aromatic hydrocarbons as risk factors. Environ. Mol. Mutagen. 39, 235-244
85. Jeffy, B.D. et al. (2002) Activation of the aromatic hydrocarbon receptor pathway is not sufficient for transcriptional repression of BRCA-1: requirements for metabolism of benzo[a]pyrene to 7r, 8t-dihydroxy-9t,10-epoxy-7,8,9,10-tetrahydrobenzo[a] pyrene. Cancer Res. 62, 113-121
86. Wang, F. et al. (2001) Transcriptional activation of cathepsin D gene expression by 17β-estradiol: mechanism of aryl hydrocarbon receptor-mediated inhibition. Mol. Cell. Endocrinol. 172, 91-103
87. Chen, I. et al. (1998) Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 19, 1631-1639
88. 2-induced expression of BRCA1 by persistent organochlorines. Breast Cancer Res. 4, R12
89. Sharan, S.K. et al. (1997) Embryo lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386, 804-810
90. Ludwig, T. et al. (1997) Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, Brca2/p53 nullizygous embryos. Genes Dev. 11, 1226-1241
91. Marquis, S.T. et al. (1995) The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat. Genet. 11, 17-26
92. Rajan, J.V. et al. (1997) Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. Dev. Biol. 184, 385-401
93. Phillips, K.W. et al. (1997) Brca1 is expressed independently of hormonal stimulation in the mouse ovary. Lab. Invest. 76, 419-425
94. Bennett, L.M. et al. (2000) Mice heterozygous for a Brca1 or Brca2 mutation display distinct mammary gland and ovarian phenotypes in response to diethylstilbestrol. Cancer Res. 60, 3461-3469
95. Kubista, M. et al. (2002) Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene 21, 4747-4756
96. Xu, X. et al. (1999) Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 22, 37-43
97. Huber, L.J. et al. (2001) Impaired DNA damage response in cells expressing an exon 11-deleted murine Brca1 variant that localizes to nuclear foci. Mol. Cell. Biol. 21, 4005-4015
98. Brodie, S.G. et al. (2001) Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 20, 7514-7523